Novel Disease but responding to an Old Drug: Role of Prolonged Corticosteroid Use in Prevention and Treatment of Post-Covid Interstitial Lung Disease (PC-ILD)
Coronavirus has affected more than 128 million humans worldwide with invasion in 129 countries across the globe. About 5-10 percent of these patients have pulmonary involvement in the form of COVID Pneumonia leading to ARDS. Although there are no statistics at the moment, trends show that majority will get rid of acute COVID respiratory involvement without any long-term pulmonary complications however several patients will face COVID sequel in the form of post-COVID fibrosis or post-COVID interstitial lung disease. With more and more survivors of COVID-19, long-term pulmonary complications of this infection especially Post-COVID ILD are being recognized by treating physicians which have a great impact on patient’s functionality and quality of life. Since there is no research-based internationally accepted strategy to prevent and treat Post-COVID ILD, a strategy based upon observations of treating pulmonologists was devised in the COVID management unit Sahiwal Medical College Sahiwal to prevent and treat Post COVID interstitial lung disease.
Anti-fibrotic, Fibrosis, Post-COVID sequalae, Post-COVID fibrosis, Post-COVID ILD
2- Ambardar SR, Hightower SL, Huprikar NA, Chung KK, Singhal A, Collen JF. Post-COVID-19 Pulmonary Fibrosis: Novel Sequelae of the Current Pandemic. Journal of Clinical Medicine. 2021 Jan;10(11):2452.
3- Udwadia ZF, Koul PA, Richeldi L. Post-COVID lung fibrosis: The tsunami that will follow the earthquake. Lung India. 2021 Mar 1;38(7):41.
4- Wells AU, Devaraj A, Desai SR. Interstitial Lung Disease after COVID-19 Infection: A Catalog of Uncertainties.
5- Yu M, Liu Y, Xu D, Zhang R, Lan L, Xu H. Prediction of the development of pulmonary fibrosis using serial thin-section CT and clinical features in patients discharged after treatment for COVID-19 pneumonia. Korean journal of radiology. 2020 Jun;21(6):746.
6- Wise J, Coombes R. Covid-19: The inside story of the RECOVERY trial. BMJ. 2020 Jul 8;370.
Copyright (c) 2022 Muhammad Waseem, Maryam Rafiq
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
All research articles published in the Journal of Rawalpindi Medical College (JRMC) are fully open access: immediately freely available to read, download, and share. Copyrights of all articles published in JRMC are retained by the authors. First publication rights are granted to JRMC. The journal/publisher is not responsible for subsequent uses of the work.
All articles are published under the Creative Commons Attribution (CC BY-SA 4.0) license.